23 September 2021 07:00 BST

AstraZeneca establishes new Sustainability Committee of the Board

AstraZeneca PLC announced today that the Board has established a Sustainability Committee. The Committee has been constituted to monitor the execution of the Company's sustainability strategy, to oversee the communication of the Company's sustainability activities with its stakeholders and to provide input to the Board and other Board Committees on sustainability matters. The terms of reference of the Committee are available at www.astrazeneca.com/content/dam/az/Investor_Relations/corporate-governance/AZ_Sustainability_Committee_ToRs.pdf.

The members of the Committee, all of whom are Non-Executive Directors of the Company, are Nazneen Rahman (Chairman of the Committee), Sheri McCoy, Andreas Rummelt and Marcus Wallenberg. These appointments take effect and the Committee will operate from 1 October 2021.

The establishment of a Sustainability Committee is a natural evolution of the Company's previous governance arrangement of having a single Board member with responsibility for overseeing sustainability matters on behalf of the Board.

Further information about sustainability at AstraZeneca is available at www.astrazeneca.com/sustainability.

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

Adrian Kemp
Company Secretary

AstraZeneca PLC